TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03189004

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Impact of Mobile Phone Technology to Improve Health Nutrition and Population (HNP) Service Utilization in Rural Bangladesh
Description: 1. Identification and registration of pregnant women and services for them~2. Birth notification~3. Childhood vaccination services under EPI~4. Newly married couple identification~5. e-Referral.~6. e-monitoring

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Impact of Mobile Phone Technology to Improve Health Nutrition and Population (HNP) Service Utilization in Rural Bangladesh
Description: 1. Identification and registration of pregnant women and services for them~2. Birth notification~3. Childhood vaccination services under EPI~4. Newly married couple identification~5. e-Referral.~6. e-monitoring

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Impact of Mobile Phone Technology to Improve Health Nutrition and Population (HNP) Service Utilization in Rural Bangladesh
Description: 1. Identification and registration of pregnant women and services for them~2. Birth notification~3. Childhood vaccination services under EPI~4. Newly married couple identification~5. e-Referral.~6. e-monitoring
Study: NCT03771586

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SAGE-718
Description: SAGE-718 in combination with Ketamine

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo in combination with Ketamine
Study: NCT03157505

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Purethal Birch immunotherapy
Description: Purethal birch was administered as perennial therapy: 24 months

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo and symptomatic treatment
Description: symptomatic treatment including: antihitamine drug, nasal dropps and placebo injection
Study: NCT03840694

Intervention type: OTHER
Group type: OTHER
Intervention: Smoking Abstinence
Description: Participants will abstain from smoking for 24 hours.

Intervention type: OTHER
Group type: OTHER
Intervention: Ad Lib Smoking
Description: Participants will continue smoking as usual (i.e. ad lib) and smoke one cigarette of their own brand immediately prior to scanning.
Study: NCT03203421

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: ChAdOx1 LS2
Description: A viral vectored vaccine, using a chimpanzee adenovirus as a vector encoding malaria liver-stage dual antigen LS2 (LSA1 and LSAP2) fused with the transmembrane domain from shark invariant chain.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: ChAdOx1 LS2
Description: A viral vectored vaccine, using a chimpanzee adenovirus as a vector encoding malaria liver-stage dual antigen LS2 (LSA1 and LSAP2) fused with the transmembrane domain from shark invariant chain.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: MVA LS2
Description: Modified vaccinia Ankara vector encoding liver-stage dual antigen LS2 (LSA1 ad LSAP2) fused to the C-terminal end of the leader sequence of tPA.
Study: NCT02838082

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sleep Hygiene Protocol
Description: Sleep Hygiene Protocol involving 1) Improved sleep environment 2) Enhanced Circadian Stimuli 3) Increased Daytime Activation (blue light therapy, daytime light exposure and daytime sleep restriction) 4) Adjusted morning ADL routines and 5) Restricted Caffeine intake

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care
Description: All standard of care procedures in a specialized traumatic brain injury inpatient rehabilitation unit
Study: NCT00813319

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Girls OnGuard
Description: Using the Information-Motivation-Behavioral Skills Model (IMB) as a framework, Girls OnGuard is an interactive,culturally-appropriate, computer-delivered program design to enhance initial uptake of GARDASIL by addressing three major components: (1) information about GARDASIL; (2) motivation to obtain GARDASIL vaccination; and (3) behavioral skills to enhance self-efficacy of obtaining GARDASIL vaccination.
Study: NCT02012296

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: enzalutamide
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: enzalutamide
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mifepristone
Description: Given PO

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: laboratory biomarker analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: pharmacological study
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Correlative studies
Study: NCT04616196

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NKTR-255
Description: NKTR-255 IV every 21 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NKTR-255
Description: NKTR-255 IV every 21 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NKTR-255
Description: NKTR-255 IV every 21 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NKTR-255
Description: NKTR-255 IV every 21 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NKTR-255
Description: NKTR-255 IV every 21 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NKTR-255
Description: NKTR-255 IV every 21 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: Cetuximab will be given at specified doses on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: Cetuximab will be given at specified doses on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: Cetuximab will be given at specified doses on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: Cetuximab will be given at specified doses on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: Cetuximab will be given at specified doses on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: Cetuximab will be given at specified doses on specified days
Study: NCT03618186

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Tau PET scan
Description: Patient will receive a dose of flutaucipir and be scanned appropriately

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Tau PET scan
Description: Patient will receive a dose of flutaucipir and be scanned appropriately

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Tau PET scan
Description: Patient will receive a dose of flutaucipir and be scanned appropriately
Study: NCT01889303

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DC
Description: Docetaxel plus cisplatin chemotherapy regimen was delivered as chemotherapy and concurrent chemoradiotherapy.~chemotherapy regimen: Docetaxel（Qilu Pharma. China） 75mg iv D1, Cisplatin（Qilu Pharma. China） 75mg iv D1 ,Q3W for 2 cycles, then Docetaxel 35mg iv D1, Cisplatin 25mg iv D1,QWx4 cycles(but rest in the 4th week during RT) + RT 45Gy( 5weeks) for concurrent chemoradiotherapy→ Rest for 4 weeks → Docetaxel 75mg iv D1,Cisplatin 75mg iv D1 ,Q3W for 2 cycles.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: concurrent chemoradiotherapy with 5-FU/CF
Description: FOLFOX6 regiment was delivered as adjuvant chemotherapy and 5-FU/CF as concurrent chemotherapy treatment.~Adjuvant chemotherapy: FOLFOX6 regiment : Oxaliplatin（Hengrui Medicine Co., Ltd，China） 85mg/m2 IV d1, Leucovorin （Hengrui Medicine Co., Ltd，China）400mg/m2 IV d1, 5-FU（Hengrui Medicine Co., Ltd，China） 400mg/m2 IV bolus d1, followed with 2400mg/m2 over 46h continuous infusion Q2Wx3 cycles of chemotherapy Concurrent chemotherapy : 5-FU 400mg/m2 IV and Leucovorin 20mg/m2 IV were given on the first four and the last three days in the period of radiotherapy. After radiation, patients will have a rest lasting for 4 weeks and then given Folxof6 regiment chemotherapy for 3 cycles.

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: radiation
Description: Therapy plan system was formulated by CT simulation. Radiation was delivered with 15MV photons in both Arm A and Arm B. Radiotherapy consisted of 45Gy of radiation at 1.8Gy/day, five days per week for 5 weeks, to the tumor bed, to the margins of resection, to the regional nodes. Protection of spinal cord, heart, liver and kidney should be considered.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation
Description: Therapy plan system was formulated by CT simulation. Radiation was delivered with 15MV photons in both Arm A and Arm B. Radiotherapy consisted of 45Gy of radiation at 1.8Gy/day, five days per week for 5 weeks, to the tumor bed, to the margins of resection, to the regional nodes. Protection of spinal cord, heart, liver and kidney should be considered.
Study: NCT01326078

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: propofol
Description: 3 - 4 mg/kg IV, adjustment dose if necessary

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: propofol
Description: 3 - 4 mg/kg IV, adjustment dose if necessary
Study: NCT00838214

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: budesonide
Description: 3mg capsule, 3x per day for 6 months

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: prednisone
Description: 5mg tablet, 40mg starting dose per day, titration to 10mg per day within 3 months
Study: NCT02433171

Intervention type: PROCEDURE
Intervention: Standard of Care FDG-PET Imaging
Description: \[11C\]Methionine \[11\]. This natural amino acid, and its various fluorinated derivatives, has been widely used in brain tumor studies due to a) high tumor-to-normal brain contrast, and b) its sensitivity to biological functions including amino acid transport and utilization. \[11C\]PBR28 \[12\]. This ligand is one of a series of second-generation tracers that bind to TSPO (translocator protein), a protein that is upregulated in activated microglia.

Intervention type: PROCEDURE
Intervention: Standard of Care FDG-PET Imaging
Description: \[11C\]Methionine \[11\]. This natural amino acid, and its various fluorinated derivatives, has been widely used in brain tumor studies due to a) high tumor-to-normal brain contrast, and b) its sensitivity to biological functions including amino acid transport and utilization. \[11C\]PBR28 \[12\]. This ligand is one of a series of second-generation tracers that bind to TSPO (translocator protein), a protein that is upregulated in activated microglia.
Study: NCT04830150

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Supportive interventions on the stress levels of mothers of infants hospitalized in the Neonatal Intensive Care Unit (NICU).
Description: This study was conducted to determine the effects of supportive interventions on the stress levels of mothers of infants hospitalized in the Neonatal Intensive Care Unit (NICU).
Study: NCT01968395

Intervention type: DRUG
Group type: OTHER
Intervention: Caspofungin 70 mg
Description: Intravenous use
Study: NCT01580033

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: A+C+hib Conjugate Vaccine
Description: The group A, C polysaccharide meningococcal and type b haemophilus influenzal conjugate vaccine (Wuxi Royal Biological Co., LTD, 20110101) will be administered on one arm, intramuscularly, per 0.5ml dose

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo will be administered intramuscularly on the other arm, intramuscularly, per 0.5ml dose

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: A+C Vaccine
Description: The group A, C polysaccharide meningococcal vaccine (Yunnan Walvax Biotechnology Co., LTD, 20101202) will be administered intramuscularly on one arm, per 0.5ml dose

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Hib vaccine
Description: The type b haemophilus influenzal vaccine (Sanofi Pasteur Limited) will be administered intramuscularly on the other arm, per 0.5ml dose
Study: NCT04433806

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Referral to weight loss program
Description: 16 weeks Diabetes Prevention Program based weight loss program at a local community partner
Study: NCT01145716

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Arthroscopy, surgery
Description: Ulno-volar wrist approach to the TFCC
Study: NCT03767036

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tramadol hydrochloride 25 mg capsule
Description: Capsule with tramadol hydrochloride 25 mg; Product of Grünenthal de Mexico S.A. de C.V.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tramadol hydrochloride 25 mg capsule
Description: Capsule with tramadol hydrochloride 25 mg; Product of Grünenthal de Mexico S.A. de C.V.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketorolac Tromethamine 10 mg tablet
Description: Tablet with ketorolac tromethamine 10 mg; Product of Siegfried Rhein, S.A. de C.V., Mexico

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketorolac Tromethamine 10 mg tablet
Description: Tablet with ketorolac tromethamine 10 mg; Product of Siegfried Rhein, S.A. de C.V., Mexico
Study: NCT04090853

Intervention type: DEVICE
Group type: OTHER
Intervention: Venus Bliss
Description: The investigational device (Venus Bliss™) is a non-invasive medical aesthetic device designed for body contouring. The device is comprised of a console, four 1064 nm diode laser applicators (60 mm x 60 mm). A belt is included to allow the operator to secure the laser applicators on the lipolysis treatment area, allowing hands free operation. The device uses vacuum assisted radiofrequency (RF) and PEMF (pulsed electromagnetic field) technology which has been shown in clinical studies to be safe and effective in body circumferential reduction and skin tightening.
Study: NCT04299191

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LAM561
Description: Once a patient is allocated a dose of LAM561, they will receive the same dose on a daily basis in treatment cycles of 21 days (3 weeks), which may be repeated without therapy interruption until a criterion for discontinuation (clinical or radiological progression of disease, clinically unacceptable toxicity, or another general criterion) is met.~The starting dose will be 2.8 g/m2 twice daily. If tolerated, doses will be escalated to 3.5 g/m2 twice daily and then to a third dose level of 4.2 g/m2 twice daily. These dose levels correspond to 80%, 100%, and 120% of the maximum tolerated dose of LAM561 in adult patients when adjusted for body surface area. A total of 3 dose cohorts are anticipated for the dose escalation phase of the study, with up to 6 patients enrolled at each dose level according to a standard 3+3 design. During each dose cohort, at least 1 week must elapse between the first and subsequent patients receiving treatment with LAM561.
Study: NCT00846651

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Colloid administration
Description: The patients received 0.5 L colloid solution (hydroxyethylstarch 6%) or 1.5 L Ringer lactate prior to spinal anesthesia for cesarean section.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Crystalloid administration
Description: The patients received 1.5 L Ringer lactate prior to spinal anesthesia for cesarean section.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: phenylephrine infusion
Description: A phenylephrine infusion will be started immediately after performing the spinal anesthesia and continued until time of uterine incision.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: phenylephrine infusion
Description: A phenylephrine infusion will be started immediately after performing the spinal anesthesia and continued until time of uterine incision.
Study: NCT03189004

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Impact of Mobile Phone Technology to Improve Health Nutrition and Population (HNP) Service Utilization in Rural Bangladesh
Description: 1. Identification and registration of pregnant women and services for them~2. Birth notification~3. Childhood vaccination services under EPI~4. Newly married couple identification~5. e-Referral.~6. e-monitoring

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Impact of Mobile Phone Technology to Improve Health Nutrition and Population (HNP) Service Utilization in Rural Bangladesh
Description: 1. Identification and registration of pregnant women and services for them~2. Birth notification~3. Childhood vaccination services under EPI~4. Newly married couple identification~5. e-Referral.~6. e-monitoring
Study: NCT01794520

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Each dose of venetoclax was to be taken with approximately 240 mL of water. On days that pre-dose pharmacokinetic (PK) sampling was required, dosing was to occur in the morning at the clinic at approximately 0900 (± 1 hour) to facilitate PK sampling. Dose Escalation cohort participants were to take venetoclax within 30 minutes after the completion of a standard low-fat breakfast with approximately 240 mL of water on Cycle 2 Day 1. On all other dosing days, participants were instructed to take venetoclax orally QD within 30 minutes after the completion of a low-fat breakfast. Tablets were to be swallowed whole and must not have been broken, chewed, or crushed.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Tablets were administered by mouth per the dexamethasone prescribing information.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Tablets were administered by mouth per the dexamethasone prescribing information.
Study: NCT02276664

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self-Help (SHI)
Description: The newly revised Stop Smoking for Good booklets.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care (UC)
Description: The existing Clearing the Air smoking-cessation manual published by the National Cancer Institute (NCI).
Study: NCT04327830

Intervention type: OTHER
Intervention: Decisional needs assessment
Description: Assessment of decision-making needs

Intervention type: OTHER
Intervention: Decisional needs assessment
Description: Assessment of decision-making needs
Study: NCT04558463

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Favipiravir
Description: The favipiravir group received loading dose of 1600 mg twice a day (3200 mg/day) on the first day and continued with 600 mg twice a day (1200 mg/day) for the next 2nd - 7th day in addition to the standard therapy.~Standard therapy: administration of azithromycin 500 mg/day or levofloxacin 750 mg/day for 5 days, chloroquine (either Sulphur-based chloroquine 600 mg/day or chloroquine phosphate 100 mg/day or hydroxychloroquine 400 mg/day) for 5-7 days, vitamin C, oxygen therapy according to the patients clinical condition, comorbid therapy and other symptomatic treatment such as antipyretic drug

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oseltamivir 75mg
Description: The oseltamivir group was given twice a day of 75 mg of oseltamivir (150 mg/day) for 7 days in addition to standard therapy~Standard therapy: administration of azithromycin 500 mg/day or levofloxacin 750 mg/day for 5 days, chloroquine (either Sulphur-based chloroquine 600 mg/day or chloroquine phosphate 100 mg/day or hydroxychloroquine 400 mg/day) for 5-7 days, vitamin C, oxygen therapy according to the patients clinical condition, comorbid therapy and other symptomatic treatment such as antipyretic drug
Study: NCT05594316

Intervention type: DRUG
Group type: OTHER
Intervention: Trichloroacetic acid
Description: 5. Patients will be subjected to 3 session of trichloroacetic acid 35% one month apart.
Study: NCT04030039

Intervention type: DRUG
Intervention: Interferon
Description: chronic hepatitis B patients with interferon therapy

Intervention type: DRUG
Intervention: Interferon
Description: chronic hepatitis B patients with interferon therapy

Intervention type: DRUG
Intervention: Interferon
Description: chronic hepatitis B patients with interferon therapy

Intervention type: DRUG
Intervention: Interferon
Description: chronic hepatitis B patients with interferon therapy

Intervention type: DRUG
Intervention: nucleoside analogues
Description: chronic hepatitis B patients with interferon therapy

Intervention type: DRUG
Intervention: nucleoside analogues
Description: chronic hepatitis B patients with interferon therapy

Intervention type: DRUG
Intervention: nucleoside analogues
Description: chronic hepatitis B patients with interferon therapy
Study: NCT01667081

Intervention type: DRUG
Intervention: Grazoprevir
Description: Participants previously received study treatment with grazoprevir at the dose and frequency specified in the study protocol. Grazoprevir was not administered to participants in the course of this follow-up study.
Study: NCT00647153

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Pre-infusion and 30 min., 1h,2h, and 3-4h post start of infusion. Day 1 and 2 post infusion.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: single photon emission computed tomography
Description: One day post infusion

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: iodine I 123 anti-CEA recombinant diabody T84.66
Description: 10mCi/mg
Study: NCT01847430

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Engerix™-B Kinder
Description: Single dose administered intramuscularly in the deltoid region of non-dominant arm at Day 0.
Study: NCT03685864

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Suture Embedding Acupuncture
Description: Suture Embedding Acupuncture at 8 acupoints (both sides of BL23, BL24, BL25, BL37). Receiving intervention 1 time in 2 weeks, and total receive 3 times.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham Acupuncture
Description: Sham Acupuncture at 8 acupoints (both sides of BL23, BL24, BL25, BL37). Receiving intervention 1 time in 2 weeks, and total receive 3 times.